These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of Roux-en-Y gastric bypass on the remission of type 2 diabetes: a 3-year study in Chinese patients with a BMI <30 kg/m2.
    Author: Di J, Zhang H, Yu H, Zhang P, Wang Z, Jia W.
    Journal: Surg Obes Relat Dis; 2016 Aug; 12(7):1357-1363. PubMed ID: 27387699.
    Abstract:
    BACKGROUND: Roux-en-Y gastric bypass (RYGB) is an effective treatment for patients with type 2 diabetes (T2D) and morbid obesity. However, T2D remission after surgery has not been adequately studied in Chinese patients with a body mass index (BMI)<30 kg/m2. OBJECTIVES: The objective of this study was to evaluate the 3-year effect of RYGB among patients with T2D with a BMI<30 kg/m2 and elucidate the predictors of T2D remission. SETTING: Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. METHODS: Sixty-six Chinese patients with T2D and a BMI 25-30 kg/m2 were retrospectively examined for metabolic outcomes 3 years after RYGB. Remission was defined as glycated hemoglobin (HbA1C)<6.5% and no medications. Binary logistic regression analysis was used to identify preoperative parameters independently predictive of diabetes remission at 1 and 3 years postoperatively [variables: sex, age, BMI, T2D duration, plasma glucose 2 hours after meal, HbA1C, fasting C-peptide, visceral fat area, free triiodothyronine, and thyroid-stimulating hormone. There was no significant difference in fasting insulin or glucose between the remission and no remission groups. RESULTS: Patients were a mean 50.4±11.4 years of age at baseline, and 57.6% were female. Mean T2D duration was 8.9±5.2 years, baseline HbA1C level was 8.3±1.9%, and baseline BMI was 28.2±1.2 kg/m2 (range: 25.5-30.0). BMI was 22.5±1.8 kg/m2 (range: 19.1-28.0) at 1 year and 23.0±1.76 kg/m2 (range: 19.7-28.0) at 3 years. Remission was achieved in 49 patients (74.2%) at 1 year and 38 patients (57.6%) at 3 years. There was a significant reduction in medication for diabetes, hypertension, and hyperlipidemia (P<.01). Compared with patients in the no remission group, patients in the remission group had higher fasting C-peptide levels (P<.01) and free triiodothyronine levels (P = .01) at 1 year. Multiple logistic regression analysis confirmed that fasting C-peptide (odds ratio = 3.795, P = .007) and free triiodothyronine (odds ratio = 4.661, P = .019) levels were predictors of T2D remission at 1 year. No significant difference was found between the 2 groups at 3 years. CONCLUSIONS: RYGB resulted in significant clinical and biochemical improvements in Chinese patients with BMI 25-30 kg/m2 and T2D. Appropriate patient selection (better β-cell function) may produce better outcomes.
    [Abstract] [Full Text] [Related] [New Search]